Ceftazidime

Ceftazidime
Clinical data
Pronunciation	/sɛfˈtæzɪdiːm/; sef-TAZ-i-deem
Trade names	Fortaz, Tazicef, others
AHFS/Drugs.com	Monograph
MedlinePlus	a686007
License data	EU EMA: by INN; US DailyMed: Ceftazidime;
Pregnancy; category	AU: B1;
Routes of; administration	Intravenous, intramuscular, inhalation
Drug class	Third-generation cephalosporin
ATC code	J01DD02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: WARNINGRx-only;
Pharmacokinetic data
Bioavailability	91% (IM)
Metabolism	negligible
Elimination half-life	1.6–2 hours
Excretion	90–96% kidney
Identifiers
	IUPAC name (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetamido)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate;
CAS Number	72558-82-8 ;
PubChem CID	5481173;
DrugBank	DB00438 ;
ChemSpider	4587145 ;
UNII	DZR1ENT301;
ChEBI	CHEBI:3508 ;
ChEMBL	ChEMBL44354 ;
CompTox Dashboard (EPA)	DTXSID5022770 ;
ECHA InfoCard	100.069.720
Chemical and physical data
Formula	C22H22N6O7S2
Molar mass	546.57 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=NOC(C(=O)O)(C)C)c3nc(sc3)N)C[n+]4ccccc4)C([O-])=O;
	InChI InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1 ; Key:ORFOPKXBNMVMKC-DWVKKRMSSA-N ;
	(what is this?) (verify)

Ceftazidime, sold under the brand name Fortaz among others, is a third-generation cephalosporin antibiotic useful for the treatment of a number of bacterial infections. Specifically it is used for joint infections, meningitis, pneumonia, sepsis, urinary tract infections, malignant otitis externa, Pseudomonas aeruginosa infection, and vibrio infection. It is given by injection into a vein, muscle, or eye.

Common side effects include nausea, allergic reactions, and pain at the site of injection. Other side effects may include Clostridium difficile diarrhea. It is not recommended in people who have had previous anaphylaxis to a penicillin. Its use is relatively safe during pregnancy and breastfeeding. It is in the third-generation cephalosporin family of medications and works by interfering with the bacteria's cell wall.

Ceftazidime was patented in 1978 and came into commercial use in 1984. It is on the World Health Organization's List of Essential Medicines. Ceftazidime is available as a generic medication.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.